Compare CTKB & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | AURA |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 777.3M | 631.6M |
| IPO Year | 2021 | 2021 |
| Metric | CTKB | AURA |
|---|---|---|
| Price | $6.32 | $7.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.50 | ★ $16.60 |
| AVG Volume (30 Days) | ★ 1.1M | 687.8K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,015,000.00 | N/A |
| Revenue This Year | $3.83 | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.67 | N/A |
| 52 Week Low | $3.31 | $4.73 |
| 52 Week High | $6.34 | $9.54 |
| Indicator | CTKB | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 60.02 | 53.31 |
| Support Level | $4.10 | $6.65 |
| Resistance Level | $6.27 | $7.04 |
| Average True Range (ATR) | 0.37 | 0.43 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 86.47 | 52.78 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.